Adenylyl cyclase 1 as a Therapy Target for Ethanol-Induced Neuroplastic Deficits

 产品说明： 该申请是CDA-2的第三次提交，此前已由VA审查小组审查过两次。 之前的申请得到了积极的审查，大多数负面评论都与指导计划有关。 此外，还有一些小的评论涉及到效果的特异性和要研究的大脑区域， 使用药理学抑制剂。 作者通过在修订后的提案中添加图8和图14做出了非常强烈的科学回应，其中她表明AC 1抑制剂组的乙醇摄入量显著降低。 我认为这是对科学部分的彻底回应。 关于指导，申请人提供了更多关于Conti博士的生产力、资历和培训的信息。 在我看来，这种回答不太令人信服。 我的总体热情水平只是中等。

 DESCRIPTION: The application is a third submission of a CDA-2 that has been reviewed by a VA review panel twice before. The previous application was reviewed favorably with the majority of the negative comments being related to the mentoring program. In addition, there were some small comments related to the specificity of the effect and the region of the brain to be studied and the use of pharmacological inhibitors. The author has responded very strongly scientifically by adding figures 8 and 14 to the revised proposal where she shows that ethanol intake is significantly decreased in the AC1 inhibitor group. I think this is a thorough response to the scientific portion. Regarding mentoring, the applicant has provided more information regarding the productivity, seniority and the training to be provided by Dr. Conti. In my opinion, this response was less convincing. My overall level of enthusiasm is only moderate.